View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 22, 2019updated 09 Aug 2019 3:04pm

Marker reports positive data from pancreatic cancer trial

Marker Therapeutics has reported positive interim results from an ongoing TACTOPS clinical trial evaluating Multi-Antigen Targeted (MultiTAA) T-cell therapy for the treatment of pancreatic adenocarcinoma.

Marker Therapeutics has reported positive interim results from an ongoing TACTOPS clinical trial evaluating Multi-Antigen Targeted (MultiTAA) T-cell therapy for the treatment of pancreatic adenocarcinoma.

The MultiTAA platform is a non-genetically modified cell therapy designed to specifically expand tumour-specific T-cells from a patient’s blood.

Marker noted that the MultiTAA platform can identify a variety of tumour antigens.

The three-arm TACTOPS trial is intended to assess the MultiTAA T-cell therapy in a total of 45 advanced or borderline resectable pancreatic adenocarcinoma patients.

Arm A of the study involves individuals with unresectable / metastatic disease responding to standard first-line chemotherapy, while Arm B is for progressive disease patients or those with therapy intolerance.

The exploratory Arm C is intended for patients with surgically resectable disease. To date, 19 participants have been treated with MultiTAA T-cell therapy infusions.

Out of the nine evaluable Arm A patients, three patients achieved objective responses with MultiTAA therapy, while four subjects had stable disease, including two with reversal of tumour growth.

One patient in the arm experienced a mixed response and another had disease progression.

Out of the six evaluable participants in Arm B, three experienced stable disease or clinical disease stabilisation and three had clinical decline after treatment with MultiTAA cells.

Arm C, evaluating T-cell infiltration and expansion, demonstrated meaningful numbers and expansion of the infused MultiTAA cells.

Findings did not reveal any infusion-related systemic or neurotoxicity.

Marker Therapeutics president and CEO Peter Hoang said: “We are encouraged by the early clinical results we have seen in this clinical trial for patients who otherwise have few therapeutic options and a dire prognostic outcome, and we are optimistic about the prospect of potentially validating the use of MultiTAA therapy in the context of first-line and second-line care for patients with pancreatic adenocarcinoma.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena